SOUTH
SAN FRANCISCO, Calif., Jan. 7, 2024
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a
precision medicine oncology company committed to the discovery and
development of targeted therapeutics, announced its participation
at the 42nd Annual J.P. Morgan Healthcare Conference and
2024 corporate guidance and program updates.
42nd Annual J.P. Morgan Healthcare Conference
Tuesday, January 9th, 2024
at 8:15 AM PT (11:15 AM ET)
- Presentation by Yujiro S. Hata,
Chief Executive Officer followed by analyst-hosted Q&A with
Anupam Rama, Managing Director, US
SMID Biotechnology Equity Research, J.P. Morgan
IDEAYA's 2024 corporate guidance and program updates
include:
- Balance sheet of $511.1 million
of cash, cash equivalents and marketable securities as of
September 30, 2023, and $134.7 million estimated net proceeds from
subsequent follow-on financing and $10
million receivable from GSK, is anticipated to fund
operations into 2028
- International site activation and double-digit patient
enrollment achieved in potential registration-enabling Phase 2/3
clinical trial of darovasertib and crizotinib combination in
first-line HLA-A2(-) metastatic uveal melanoma (MUM)
- Clinical program update(s) in 2024 for potential
registration-enabling Phase 2/3 clinical trial of darovasertib and
crizotinib combination in first-line HLA-A2(-) MUM
- Targeting clinical efficacy update from Phase 2 company
sponsored neoadjuvant uveal melanoma (UM) study in mid-year 2024
and regulatory guidance update in 2024
- Targeting ongoing enrollment of IDE397 and AMG 193 Phase 1
combination study in MTAP-deletion solid tumors and development of
joint publication strategy in 2024
- Anticipate First-Patient-In of Phase 1 IDE397 and Trodelvy®
clinical combination study in MTAP-deletion bladder cancer in
mid-year 2024
- Preliminary IDE397 clinical efficacy observed in MTAP deletion
solid tumors, including RECIST 1.1 complete response in bladder
cancer patient, 33% tumor shrinkage in NSCLC patient by CT/PET, and
multiple ctDNA molecular responses in NSCLC and bladder
cancer
- Targeting IDE161 clinical program update(s) and enabling of
clinical combination(s) in 2024
- Preliminary IDE161 clinical efficacy observed in HRD solid
tumors, including RECIST 1.1 partial responses in priority solid
tumor types and >50% PSA reduction in a prostate cancer
patient
- Targeting ongoing enrollment of IDE161 Phase 1 expansion in HRD
solid tumor priority types, including endometrial, colorectal,
prostate, and ER+ HER2- breast cancers
- Advancing Phase 1 dose escalation for GSK101 (IDE705) Pol Theta
Helicase inhibitor, and targeting IND submission in 2024 for Werner
Helicase Inhibitor Development Candidate ($7.0 million milestone upon IND clearance) under
collaboration with GSK
- Targeting multiple wholly-owned next generation development
candidate nominations in 2024, including in MTAP-deletion, further
advancing IDEAYA's multi-pronged strategy in MTAP-deletion and
AI/ML and structurally-enabled drug discovery platform
IDEAYA's updated corporate presentation reflecting its 2024
corporate guidance is available on its website, at the Investor
Relations page: https://ir.ideayabio.com/.
A live audio webcast of the event, as permitted by conference
host, will be available at the "Investors/News and Events/Investor
Calendar" section of the IDEAYA website at
https://ir.ideayabio.com/events. A replay of available webcasts
will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with drug discovery to select patient
populations most likely to benefit from its targeted
therapies. IDEAYA is applying its early research and drug
discovery capabilities to synthetic lethality – which represents an
emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to (i)
participation in and/or presentation at certain investor relations
events and (ii) 2024 corporate guidance. IDEAYA undertakes no
obligation to update or revise any forward-looking statements. For
a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to the
business of IDEAYA in general, see IDEAYA's recent Quarterly Report
on Form 10-Q filed on November 7,
2023 and any current and periodic reports filed with the
U.S. Securities and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-participation-at-the-42nd-annual-jp-morgan-healthcare-conference-and-2024-corporate-guidance-302027639.html
SOURCE IDEAYA Biosciences, Inc.